Thursday, September 03, 2020 1:36:40 PM
If the 64% theory is correct, it also means the board consists of not so smart people, willing to give away 64% the company to GEM who can replace them at a moment's notice.
I would not think so. Dr. Selvaraju is the Chairman and Dr. Javitt is the Vice Chairman of the Board. Very smart individuals, sharpest knife in the kitchen.
https://www.biospace.com/article/releases/relief-therapeutics-holding-sa-six-rlf-announces-the-proposal-of-prof-jonathan-javitt-m-d-m-p-h-at-the-upcoming-general-assembly-as-vice-chairman-of-the-board/
$RLFTF
Imho only.
I would not think so. Dr. Selvaraju is the Chairman and Dr. Javitt is the Vice Chairman of the Board. Very smart individuals, sharpest knife in the kitchen.
https://www.biospace.com/article/releases/relief-therapeutics-holding-sa-six-rlf-announces-the-proposal-of-prof-jonathan-javitt-m-d-m-p-h-at-the-upcoming-general-assembly-as-vice-chairman-of-the-board/
$RLFTF
Imho only.
Recent RLFTF News
- MindMaze Therapeutics Announces Initiation of Coverage by Baader Bank • ACCESS Newswire • 03/19/2026 06:35:00 AM
- MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics • ACCESS Newswire • 12/23/2025 06:20:00 AM
- Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics • ACCESS Newswire • 12/15/2025 06:20:00 AM
- Relief Therapeutics Shareholders Approve Business Combination with NeuroX • ACCESS Newswire • 11/14/2025 05:40:00 PM
- Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032 • ACCESS Newswire • 10/29/2025 06:20:00 AM
